Telix Pharmaceuticals Limited’s EPS Growth at a glance
Telix Pharmaceuticals Limited reports eps growth of 820.2% for Dec 2024. The prior period recorded 104.8% (Dec 2023). Year over year the metric moved +715.5 pts (+682.7%). The rolling three-period average stands at 302.6%. Data last refreshed Dec 7, 2025, 2:48 AM.
Latest reading
820.2% · Dec 2024
YoY movement
+715.5 pts (+682.7%)
Rolling average
302.6%
Current EPS Growth
820.2%
+715.5 pts
+682.7%
Rolling average
302.6%
Latest Value
820.2%
Dec 2024
YoY Change
+715.5 pts
Absolute
YoY Change %
+682.7%
Rate of change
3-Period Avg
302.6%
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s eps growth stands at 820.2% for Dec 2024. Year-over-year, the metric shifted by +715.5 pts, translating into a +682.7% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How eps growth shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports eps growth of 820.2%. Review EPS trajectory, compounding pace, and earnings momentum supported by trailing annual filings.
Understanding EPS momentum
Sustained positive EPS growth underpins long-term shareholder returns. Volatility often reflects cyclical businesses or share-count changes.
Check the drivers behind EPS
Analyze revenue growth, margin expansion, and buybacks to see which levers are powering EPS gains.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.1%
Operating Margin
10.5%
Net Profit Margin
6.4%
Return on Equity
8.8%
Return on Assets
3.3%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s eps growth profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current eps growth?
As of Dec 2024, Telix Pharmaceuticals Limited reports eps growth of 820.2%. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's eps growth trending year over year?
Year-over-year, the figure shifts by +715.5 pts (+682.7%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does eps growth matter for Telix Pharmaceuticals Limited?
Earnings-per-share growth reveals how quickly per-share net income is expanding or contracting versus the prior year. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's eps growth above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at 302.6%. Comparing the latest reading of 820.2% to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's eps growth refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:48 AM and updates automatically every 24 hours, keeping your valuation inputs current.